- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02632760
Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery (ITACS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Preoperative anaemia is common (≈30%) in patients awaiting cardiac surgery, and is associated with increased complications, ICU and hospital stay, and mortality. The extent of anaemia is worsened by haemodilution occurring with cardiopulmonary bypass and surgical bleeding (average blood loss 0.5-1.5 litres), which in turn impair end-organ blood flow and tissue oxygen delivery. Further, the need for blood transfusion is greatly increased in anaemic patients, and is associated with poor outcomes. In addition, blood transfusions are costly (>$700 per unit), with around 50% of all transfusions used in surgery being for cardiac surgery. The investigators have identified high rates of bleeding complications and transfusion requirements in Australian cardiac surgery; and in another international collaboration, it was found that anaemia, transfusion and kidney injury are inter-related after cardiac surgery. After risk-adjustment, the combination of these three risk factors was associated with a 3.5-fold (95% CI 2.3-5.2) increased odds of kidney injury.
Both anaemia and red cell transfusion are independent risk factors in major surgery. Some of the investigators reviewed Australian cardiac surgery patients from six Victorian hospitals, 2005-2011. We linked the ANZ Society of Cardiothoracic Surgeons cardiac surgery database to laboratory data, including preoperative haemoglobin and all issued blood products (manuscript in preparation). Anaemia was defined according to the WHO definition (Hb <130 g/L for males and <120 g/L for females). There were 15,948 cardiac surgery patients available for inclusion in the analysis, of which 28% were anaemic. Anaemic patients were more likely to receive a red cell transfusion (71% vs. 40%, p<0.001), more transfused units of blood (median 4 [IQR 2-8] vs. 3 [2-5], p<0.001), and had higher 30-day mortality (5.4% vs. 1.9%, p<0.001), new renal failure (43% vs. 26%, p<0.001), and longer hospital stay in survivors (13 days [8-23] vs. 8 days [6-14], p<0.001). After multivariable adjustment, preoperative anaemia was an independent predictor of mortality (adj. OR 1.46, 95% CI 1.14-1.88, p=0.003). Similar results were obtained when restricted to elective surgery, but with hospital stay 9 days (7-17) vs. 7 days (6-11), p<0.001. Other large studies are consistent with this.
The investigators have also analysed data for patients undergoing major non-cardiac surgery from the American College of Surgeons' National Surgical Quality Improvement Program database (a validated outcomes registry from 211 hospitals worldwide). In 227,425 patients undergoing noncardiac surgery, and found that preoperative anaemia was associated with increased 30-day mortality (adj. OR 1.42, 95% CI 1.31-1.54) and morbidity (adj. OR 1.35, 1.30-1.40).
Alfred hospital (Melbourne) transfusion data for 2012-14 (n=2,091) show that anaemic (27% of cohort) and non-anaemic cardiac surgical patients had intraoperative red cell transfusion rates of 31% and 14%, respectively; p<0.01.
Iron deficiency is the commonest cause of anaemia worldwide, and iron deficiency per se independently worsens outcomes after surgery. The traditional textbook definition of iron deficiency anaemia refers to depletion of the body's iron stores due to dietary deficiency or chronic blood loss - an absolute iron deficiency. Chronic disease and inflammation have a direct effect in the pathway of iron absorption and metabolism leading to a state of functional iron deficiency and anaemia. Specifically, the iron regulatory protein hepcidin is upregulated, blocking pathways of iron transport. This prevents iron absorption from the gut, further uptake by the reticuloendothelial system increases stores (ferritin), but distribution and transfer to the bone marrow is blocked. Consequently, despite normal or even increased body iron stores (with normal ferritin levels), these are artifactual, and a state of 'functional iron deficiency' exists. This is commonly seen in renal and cardiac disease and increasingly recognised as a cause for anaemia in the surgical patient. Importantly, IV iron has been shown to overcome this functional deficiency and correct anaemia.
IV iron therapy is effective in treating anaemia in medical (heart failure, kidney disease), post-partum, and preoperative settings (orthopaedic surgery, colon cancer resection, hysterectomy, hip/knee joint replacement. Earlier IV iron preparations using high molecular weight dextran were associated with anaphylaxis due to pre-formed antibodies, but newer preparations are safer, enabling delivery of a full treatment dose in 15 mins, so iron can be administered safely and quickly in outpatients. It is now readily available in Australia and is PBS-listed. This gives patients the equivalent dose of 12 months of tablets in only 15 mins.
Iron deficiency is very common in patients having coronary artery surgery. It is highly plausible that anaemia correction will improve patient outcome following cardiac surgery.However, some data suggest that free iron mediates free radical production associated with organ damage or infection in surgery and this balance between effective anaemia correction and potential risk needs further research. A definitive large trial is needed to determine if IV iron safely, effectively, and promptly corrects preoperative anaemia, and thus reduces risk in cardiac surgery.
The investigators undertook a Cochrane review of iron therapy to treat anaemia in adults including 4,745 participants in 21 trials. This found a trend for better haemoglobin levels with IV iron (MD 0.50 g/dL, 95% CI 0.73-0.27; six studies, N=769) but with considerable, unexplained heterogeneity. Differences in the proportion of participants requiring transfusion were imprecise (RR 0.84, 95% CI 0.66-1.06; 8 studies, N=1,315). Thus the current evidence base is sparse; few randomised trials have been done and these were too small - there remains considerable equipoise.
Review of the literature on anaemia and iron therapy in cardiac surgery, which included 4 small trials of IV iron. Overall, half of all cardiac surgery patients were anaemic before surgery. Preoperative anaemia was found to be independently associated with higher mortality and blood transfusion rate, as well as longer ICU and hospital stay. As also shown by others, preoperative haematocrit was a powerful independent predictor of mortality, renal failure and deep sternal wound infection. In adjusted analyses each 5 point decrease in preoperative haematocrit was associated with an 8% increased risk of death (OR, 1.08; p<0.0003), a 22% increased risk of postoperative renal failure (OR, 1.22; p<0.0001), and a 10% increased risk of deep sternal wound infection (OR, 1.10; p<0.01). There is a need for a well-designed, pragmatic trial to assess the role of preoperative anaemia treatment using IV iron in patients undergoing cardiac surgery.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Paul S Myles, MD
- Phone Number: 3176 +61390762000
- Email: p.myles@alfred.org.au
Study Contact Backup
- Name: Sophie k Wallace, MPH
- Phone Number: 2651 +61390762000
- Email: s.wallace@alfred.org.au
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3181
- Recruiting
- Alfred Health
-
Contact:
- Paul s Myles, MD
- Phone Number: 63176 +61390763176
- Email: p.myles@alfred.org.au
-
Contact:
- Sophie K Wallace, MPH
- Phone Number: 62651 +61 390762651
- Email: s.wallace@alfred.org.au
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with anaemia (males Hb <130 g/L, females <120 g/L) undergoing elective cardiac surgery, and available to receive trial drug 1- 10 weeks prior to surgery
Exclusion Criteria:
- Pregnancy
- Known hypersensitivity to study drug (ferric carboxymaltose or equivalent) or its excipients
- Known or suspected haemoglobinopathy/thalassaemia
- Bone marrow disease
- Haemochromatosis
- Renal dialysis
- Erythropoietin or IV iron in the previous 4 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo intravenous infusion
|
placebo - no active drug
Other Names:
|
Active Comparator: ferric carboxymaltose
ferric carboxymaltose 1000 mg or Iron isomaltoside 1000 mg given Intravenously
|
treatment for Iron deficient anaemia
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Days alive and out of hospital.
Time Frame: induction of anaesthesia for cardiac surgery up to 90 days post operatively
|
90 days post surgery.
the number of days the patient was not in hospital or care facility during the 90 day period from surgery.
|
induction of anaesthesia for cardiac surgery up to 90 days post operatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correction of anemia following administration of trial drug to day of surgery measure by hemoglobin
Time Frame: from administration of trial drug up to induction of anaesthesia for cardiac surgery up to 10 weeks
|
following administration of trial drug to day of surgery.
Analysis of the Haemoglobin changes.
|
from administration of trial drug up to induction of anaesthesia for cardiac surgery up to 10 weeks
|
Intensive care stay
Time Frame: induction of anaesthesia for cardiac surgery to 30 days post operatively
|
Total days in hospital and Intensive care from induction of anaesthesia for cardiac surgery up until 30 days post operation
|
induction of anaesthesia for cardiac surgery to 30 days post operatively
|
hospital stay
Time Frame: induction of anaesthesia for cardiac surgery to 30 days post operatively
|
Total days in hospital from induction of anaesthesia for cardiac surgery up until 30 days post operation
|
induction of anaesthesia for cardiac surgery to 30 days post operatively
|
Disability-free survival
Time Frame: 180 days from induction of anaesthesia for cardiac surgery
|
Using the WHODAS to measure disability post operatively up to180 days from surgery.
disability will be measured as an increased score of ≥4 for a period of ≥ 3months
|
180 days from induction of anaesthesia for cardiac surgery
|
90-day survival
Time Frame: induction of anaesthesia for cardiac surgery up to 90 days post operatively
|
mortality within 90 days from induction of anaesthesia for cardiac surgery
|
induction of anaesthesia for cardiac surgery up to 90 days post operatively
|
units of allogeneic blood transfused
Time Frame: induction of anaesthesia for cardiac surgery to discharge from hospital up to 30 days
|
number of blood products transfused
|
induction of anaesthesia for cardiac surgery to discharge from hospital up to 30 days
|
Quality of life
Time Frame: induction of anaesthesia for cardiac surgery up to 180 days post operatively
|
Quality of life after cardiac surgery
|
induction of anaesthesia for cardiac surgery up to 180 days post operatively
|
Cost-effectiveness
Time Frame: From trial drug administration to 180 days from induction of anaesthesia for cardiac surgery
|
comparative cost analysis for the use of iron v's placebo
|
From trial drug administration to 180 days from induction of anaesthesia for cardiac surgery
|
Days alive and out of hospital.
Time Frame: induction of anaesthesia for cardiac surgery up to 30 days post operatively
|
30 days post surgery.
the number of days the patient was not in hospital or care facility during the 30 day period from surgery.
|
induction of anaesthesia for cardiac surgery up to 30 days post operatively
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anaphylaxis
Time Frame: during administration of the trial drug (up to 1 hour)
|
drug or transfusion reaction
|
during administration of the trial drug (up to 1 hour)
|
Infection
Time Frame: induction of anaesthesia for cardiac surgery to 30 days post operatively
|
Surgical site infection rate following induction of anaesthesia for cardiac surgery to 30 days post operative
|
induction of anaesthesia for cardiac surgery to 30 days post operatively
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Paul S Myles, MD, Bayside Health
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 605/15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anaemia
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
International Centre for Diarrhoeal Disease Research...Completed
-
Daiichi Sankyo, Inc.Completed
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
Indian Council of Medical ResearchDelhi UniversityUnknown
Clinical Trials on Ferric carboxymaltose
-
Sichuan Huiyu Pharmaceutical Co., LtdThe First Hospital of Jilin University; Suzhou Guochen Biotek Co., Ltd.; Boji... and other collaboratorsCompletedBioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency AnaemiaIron Deficiency | AnaemiaChina
-
Hasselt UniversityZiekenhuis Oost-LimburgCompleted
-
Charite University, Berlin, GermanyUniversity of GöttingenUnknownHeart Failure | Iron-deficiencyGermany
-
The Catholic University of KoreaUnknownKnee Osteoarthritis | Total Knee Arthroplasty | Postoperative Anemia
-
The Catholic University of KoreaUnknownKnee Osteoarthritis | Total Knee Arthroplasty | Postoperative Anemia
-
St Joseph University, Beirut, LebanonSaint-Joseph University; Vifor PharmaCompletedAnemia, Iron DeficiencyLebanon
-
Istanbul UniversityRecruitingAnemia | Hip Fractures | Complication,PostoperativeTurkey
-
Vifor PharmaTerminatedIron-Deficiency AnemiaFrance, Greece
-
American Regent, Inc.Completed
-
University of ZurichTerminated